MWMarisol Wences

Marisol Wences

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marisol Wences has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of a novel Guideline Directed Medical Therapy (GDMT) scoring tool to optimize therapy for patients with heart failure with reduced ejection fraction (HFrEF)

    by Marisol Wences, Henry Okoroike, Thomas Bernier, Ahmet Afsin Oktay

    Background: The mortality benefit of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) is well established. However, contemporary registry data consistently demonstrates substantial gaps in GDMT optimization. A standardized tool to quantify GDMT optimization and target dose achievement may help identify treatment deficits, guide clinical decision-making, and improve associated patient outcomes. Methods: This retrospective, single-center observational study evaluated the internal validity of a novel GDMT scoring tool to quantify GDMT optimization. Adult patients admitted between September 2022 and September 2023 with HFrEF and outpatient follow-up were included. The primary analysis assessed the association between GDMT optimization at 30 days and the risk of 90-day all-cause hospitalization using multivariable logistic regression. Secondary analyses described GDMT optimization rates at 30 days, quadruple therapy rates, and associations between GDMT optimization and 90-day HF hospitalization and all-cause mortality. Results: Eighty-nine patients met inclusion criteria. At 30 days, 76% of patients (n= 68) achieved a GDMT score of ≥ 5 and 24% (n= 21) had a suboptimal GDMT score of P=0.008 ) though no significant differences were observed for HF hospitalizations (OR 0.55 CI 0.17-1.85, P=0.33 ) or all-cause mortality ( P=0.997 ). Conclusion: An optimized GDMT score of ≥ 5 at 30 days was associated with reduced odds of all-cause readmissions at 90 days ( P=0.008 ).